{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/acne-vulgaris/management/primary-care-management/","result":{"pageContext":{"chapter":{"id":"8708236c-483d-548a-bcbb-ece4a63d3ef2","slug":"primary-care-management","fullItemName":"Scenario: Primary care management","depth":2,"htmlHeader":"<!-- begin field 444ef8ad-de29-4bcf-85c5-6e63a8881840 --><h2>Scenario: Management of acne vulgaris in primary care</h2><!-- end field 444ef8ad-de29-4bcf-85c5-6e63a8881840 -->","summary":"Covers the management of mild, moderate and severe acne in primary care.","htmlStringContent":"<!-- begin item d43f4f12-7320-43eb-85e5-3850f851c684 --><!-- begin field eeeba9b8-831e-44c0-9621-acbc01580b05 --><p>From age 12 years onwards.</p><!-- end field eeeba9b8-831e-44c0-9621-acbc01580b05 --><!-- end item d43f4f12-7320-43eb-85e5-3850f851c684 -->","topic":{"id":"4f10413c-64a7-5bb3-9003-1093b58e5700","topicId":"7737f6eb-1907-461e-a10b-166056e652b7","topicName":"Acne vulgaris","slug":"acne-vulgaris","lastRevised":"Last revised in August 2020","chapters":[{"id":"c13b5a16-bcf3-5b36-8dce-af226250264d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"318cce93-72af-5473-9c96-2577e69df14c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6aac7922-c920-5394-bc2c-08ae3e93e4c5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b6ea59d7-e11c-59ba-ae3a-d12eda1c224b","slug":"changes","fullItemName":"Changes"},{"id":"501eff80-f5ab-5966-b79a-791cec9fcf7c","slug":"update","fullItemName":"Update"}]},{"id":"017f5393-8a9f-5cdb-9799-d9c32c6b50e9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"32769738-e7d1-5c7a-a6ac-7e242b6ad659","slug":"goals","fullItemName":"Goals"},{"id":"60cde7a9-d789-5629-a7d6-e14882c6caf9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f91e328f-4d37-5a01-ab6d-edf7165acdaf","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"01961474-a4a0-5330-bc03-aca2c93fd7ed","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"867bb680-22ea-5d29-88b0-f219f9e8dae8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8447443c-c6e1-5af4-ab33-68aa460c97b0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"10279ff1-6a1f-5af9-97b1-73405139911f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"13ced928-40f6-593c-8ae8-3d619c885e2e","slug":"definition","fullItemName":"Definition"},{"id":"290d67e9-4d5f-5a03-bafc-46380a14e964","slug":"causes","fullItemName":"Causes"},{"id":"2c90cfb7-ff4f-535b-b067-7b291de8de21","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5665dddd-4418-59f5-8480-8d73bc88b392","slug":"complications","fullItemName":"Complications"},{"id":"8e63da8e-8783-584a-962f-77fc8f5cda7c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"cac20ff4-4d28-5a3d-ab66-5ad66ea6485d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"318b12a5-f38e-5aa0-866d-258e0bc4606b","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"00cb6f19-98f0-5279-8ca3-56e9898a856b","slug":"assessment","fullItemName":"Assessment"},{"id":"9a6b352b-2522-507b-baee-3746ed6c5fc1","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"93060cf3-048d-55d8-b979-1ee7c8b333d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"8708236c-483d-548a-bcbb-ece4a63d3ef2","slug":"primary-care-management","fullItemName":"Scenario: Primary care management"}]},{"id":"ff879f6d-4cca-54e7-b137-1bea3673664f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c9958ec-2ef2-5cdd-8066-9039ba251071","slug":"benzoyl-peroxide","fullItemName":"Benzoyl peroxide"},{"id":"6d9ac0d3-8378-55b8-b6dc-17fb87472c20","slug":"topical-retinoids","fullItemName":"Topical retinoids"},{"id":"b3431b25-388f-5ae4-9ae3-fe13143c5d26","slug":"topical-antibiotics","fullItemName":"Topical antibiotics"},{"id":"9ca57669-ad06-5179-885d-5b8063e1323f","slug":"azelaic-acid","fullItemName":"Azelaic acid"},{"id":"8ae4cfcf-ffa5-5d2f-b469-369a52c50963","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"dd897071-f76b-5e49-9c2d-e98f4b853afa","slug":"combined-oral-contraceptives","fullItemName":"Combined oral contraceptives"}]},{"id":"1a455bee-cdcd-5bfe-ac3c-92ebf7dc4f1b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c326d983-7898-5757-a2dd-0324dc5bca9a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7efc9e19-3f3c-5fe4-86af-6645e982294d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5133582b-9a2b-5faf-a3be-a014b639deef","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"10179a08-abca-5ecd-982e-b1147cb710a3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"25e71f93-96a6-5694-a7be-371938647a37","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2adb6ee6-1991-50db-bb70-4a7b3d113064","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9f2f3c9d-3968-50fd-88cb-555214f14d6b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"93060cf3-048d-55d8-b979-1ee7c8b333d0","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"b3ddb43f-a8c4-5295-be95-6c758f0b9723","slug":"primary-care-management","fullItemName":"Primary care management","depth":3,"htmlHeader":"<!-- begin field 09984693-6e2c-4504-a5ac-9851a0d7aa69 --><h3>How should I manage a person with acne vulgaris in primary care?</h3><!-- end field 09984693-6e2c-4504-a5ac-9851a0d7aa69 -->","summary":null,"htmlStringContent":"<!-- begin item 2653f225-5439-42a0-af35-1de05fa674b4 --><!-- begin field 32004ce2-340a-4a67-9c00-bb8f07b21c9e --><ul><li><strong>Explain the diagnosis and provide patient information:</strong><ul><li>Discuss treatment aims.</li><li>Advise the person:<ul><li>To avoid over cleaning the skin (which may cause dryness and irritation). Acne is not caused by poor hygiene and twice daily washing with a gentle soap and fragrance-free cleanser is adequate.</li><li>If make-up, cleansers and/or emollients are used, non-comedogenic preparations with a pH close to the skin are recommended.</li><li>To avoid picking and squeezing spots which may increase the risk of scarring.</li><li>That treatments are effective but take time to work (usually up to 8 weeks) and may irritate the skin, especially at the start of treatment.</li><li>To maintain a healthy diet.</li></ul></li><li>Patient information is available from:<ul><li>NHS A-Z — <a data-hyperlink-id=\"f4dd7ca5-0e47-4642-bd54-a992015953eb\" href=\"https://www.nhs.uk/conditions/acne/\" target=\"_blank\">Acne</a>.</li><li>British Association of Dermatologists — <a data-hyperlink-id=\"42c95430-af1a-4812-aa67-a9920159540b\" href=\"http://www.bad.org.uk/for-the-public/patient-information-leaflets\" target=\"_blank\">Acne</a>.</li></ul></li></ul></li><li><strong>For people with mild-to-moderate acne:</strong><ul><li>Consider prescribing a single topical treatment such as:<ul><li>A topical retinoid (for example adapalene [if not contraindicated]) alone or in combination with benzoyl peroxide. Retinoids are contraindicated in pregnancy and breastfeeding.</li><li>A topical antibiotic (for example clindamycin 1%) — antibiotics should always be prescribed in combination with benzoyl peroxide to prevent development of bacterial resistance. Topical benzoyl peroxide and topical erythromycin are usually considered safe in pregnancy if treatment is felt to be necessary.</li><li>Azelaic acid 20%.</li></ul></li><li>Creams or lotions may be preferable for people with dry or sensitive skin and less greasy gels may be preferable for people with oily skin.</li><li>Concentration or application frequency of topical treatments may need to be reduced or lowered if skin irritation occurs.<ul><li>Advise the person that frequency of application can be gradually increased from once or twice a week to daily if tolerated.</li></ul></li></ul></li><li><strong>For people with moderate acne not responding to topical treatment:</strong><ul><li>If response to topical preparations alone is inadequate consider adding an oral antibiotic, a tetracycline, such as lymecycline or doxycycline (for a maximum of 3 months).<ul><li>A topical retinoid (if not contraindicated) or benzoyl peroxide should always be co-prescribed with oral antibiotics to reduce the risk of antibiotic resistance developing.</li><li>Macrolide antibiotics (such as erythromycin) should generally be avoided due to high levels of <em>P. acnes</em> resistance but can be used if tetracyclines are contraindicated (for example in pregnancy if treatment is felt to be necessary).</li><li>Change to an alternative antibiotic if there is no improvement after 3 months, the person is unable to tolerate side effects or acne worsens while on treatment.</li><li>If the person does not respond to two different courses of antibiotics, or if they are starting to scar, refer to a dermatologist for consideration of treatment with isotretinoin.</li></ul></li><li>Combined oral contraceptives (if not contraindicated) in combination with topical agents can be considered as an alternative to systemic antibiotics in women.<ul><li>Oral progesterone only contraceptives or progestin implants with androgenic activity may exacerbate acne, third and fourth generation combined oral contraceptives are generally preferred.</li><li>Co-cyprindiol (Dianette®) or other ethinylestradiol/cyproterone acetate containing products may be considered in moderate to severe acne where other treatments have failed but require careful discussion of the risks and benefits with the patient. Use should be discontinued 3 months after acne has been controlled and prescription guided by the UK Medical Eligibility Criteria for Contraceptive Use and the Summary of Product Characteristics for the individual product.</li><li>For further information on contraceptives, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a>.</li></ul></li></ul></li><li><strong>Refer the person to dermatology, with urgency depending on the clinical situation if:</strong><ul><li>They have a severe variant of acne such as <a class=\"topic-reference internal-reference\" href=\"/topics/acne-vulgaris/background-information/definition/\">acne conglobata</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/acne-vulgaris/background-information/definition/\">acne fulminans</a> (immediate referral is indicated).</li><li>They have severe acne associated with visible scarring or are at risk of scarring or significant hyperpigmentation — primary care treatment should be initiated in the interim.</li><li>Multiple treatments in primary care have failed.</li><li>Significant psychological distress is associated with acne regardless of severity — primary care treatment should be initiated in the interim.</li><li>There is diagnostic uncertainty.</li></ul></li><li><strong>Arrange follow-up</strong><ul><li>Review each treatment step at 8-12 weeks.<ul><li>If there has been an adequate response continue treatment for at least 12 weeks.</li><li>If acne has cleared or almost cleared — consider maintenance therapy with topical retinoids (first line, if not contraindicated) or azelaic acid.</li><li>If there has been no response consider adherence to treatment, adverse effects, progression to more severe acne, or use of comedongenic make up or face creams. Discuss a trial of an alternative formulation or move on to the next step in treatment if appropriate.</li></ul></li></ul></li></ul><!-- end field 32004ce2-340a-4a67-9c00-bb8f07b21c9e --><!-- end item 2653f225-5439-42a0-af35-1de05fa674b4 -->","subChapters":[{"id":"9082d229-c7cc-5ea8-9f4e-8661cc35a6c9","slug":"basis-for-recommendation-a5f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 03513199-27bd-4315-9c32-eb866d6a3067 --><h4>Basis for recommendation</h4><!-- end field 03513199-27bd-4315-9c32-eb866d6a3067 -->","summary":null,"htmlStringContent":"<!-- begin item a5f25f97-66a5-4493-895a-f4880f3308e8 --><!-- begin field 37c1c536-83b7-4973-b63e-82139684d0d3 --><p>The recommendations on the management of acne in primary care are based on the clinical guidelines <em>Evidence-Based Recommendations for the Diagnosis and Treatment of Pediatric Acne</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Eichenfield, 2013</a>], <em>Strengthening of warnings about use of Dianette and other brands of co-cyprindiol</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">FSRH, 2013</a>], <em>Management of acne: Canadian clinical practice guideline</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Asai, 2016</a>], <em>A consensus-based practical and daily guide for the treatment of acne patients</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>], <em>European evidence-based (S3) guideline for the treatment of acne – update 2016</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Nast, 2016</a>], <em>Guidelines of care for the management of acne vulgaris</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>], and <em>Acne: acne vulgaris</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">PCDS, 2018</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Dawson, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Archer et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Kong, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Botros, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Moradi Tuchayi, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Sinnott, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Walsh, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">BMJ Best Practice, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gebauer, 2017</a>].</p><h5>General advice</h5><ul><li><strong>Cleansing</strong> — Acne is not caused by poor hygiene. Aggressive washing can aggravate acne and should be avoided [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Eichenfield, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">PCDS, 2018</a>].</li><li><strong>Healthy diet</strong> — The role of diet in acne remains poorly understood — emerging data suggests that high glycaemic index (GI) diets may exacerbate acne [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">PCDS, 2018</a>].</li></ul><h5>Topical treatment</h5><ul><li>UK, European and International guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Asai, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Nast, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">PCDS, 2018</a>] recommend the use of topical agents including benzoyl peroxide, topical retinoids and topical antibiotics for mild to moderate acne.<ul><li>Benzoyl peroxide is antibacterial and mildly comedolytic — it is effective in mild to moderate acne and both comedones and inflamed lesions respond well [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">BNF 74, 2017</a>].<ul><li>Addition of benzoyl peroxide to topical antibiotic therapies is recommended to reduce the risk of antibiotic resistance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Asai, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Nast, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">PCDS, 2018</a>].</li></ul></li><li>Topical retinoids are comedolytic, anti-comedogenic, anti-inflammatory and inhibit formation of microcomedones (the precursors to acne lesions) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>].<ul><li>Topical retinoids have been found to be effective in the treatment of comedonal acne and, when used in combination with other drugs for all acne variants [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Dawson, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>].</li><li>The European evidence-based (S3) guideline for the treatment of acne – update 2016 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Nast, 2016</a>] recommends that adapalene is used in preference to other topical retinoids (such as tretinoin and isotretinoin).</li></ul></li><li>Topical antibiotics are thought to work through anti-inflammatory and anti-bacterial effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>].<ul><li>Topical monotherapy with antibiotics is not recommended because of the risk of antibiotic resistance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Eichenfield, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Asai, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Nast, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>].</li><li>The American Academy of Dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>] recommend Clindamycin 1% solution or gel as the preferred topical antibiotic for acne.</li></ul></li><li>Azelaic acid<ul><li>Azelaic acid is mildly effective as a comedolytic, antibacterial, and anti-inflammatory agent [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>]. It is recommended as second-line treatment in several guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Nast, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">PCDS, 2018</a>].</li><li>Some people may prefer azelaic acid to benzoyl peroxide as it is less likely to cause skin irritation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">BNF 74, 2017</a>].</li></ul></li></ul></li></ul><h5>Systemic antibiotics</h5><ul><li>UK, European and International guidelines and expert opinion recommend combining systemic antibiotics with an appropriate topical agent, such as benzoyl peroxide or a topical retinoid to reduce bacterial resistance and target the different pathophysiological mechanisms in acne [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Walsh, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Bienenfeld, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">PCDS, 2018</a>].<ul><li>Although tetracycline and doxycycline have been shown to be superior to placebo in reducing inflammatory acne lesions these drugs should not be prescribed in isolation due to the risk of selection of antibiotic resistant bacteria [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Asai, 2016</a>].</li><li>Minocycline is not recommended for use in acne as it is associated with an increased risk of drug­ induced lupus, skin pigmentation and hepatitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Eichenfield, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">PrescQIPP, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Asai, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Nast, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">BNF 74, 2017</a>].</li><li>Macrolides should be avoided in the treatment of acne (unless tetracyclines are contraindicated or cannot be tolerated) due to increased bacterial resistance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Eichenfield, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Bienenfeld, 2017</a>].</li></ul></li><li>Evidence suggests that there is little additional benefit in using antibiotics for more than three months, and in addition, prolonged use increases the resistance of <em>P.acnes</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zouboulis, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Nast, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">PCDS, 2018</a>].<ul><li>Antibiotic courses can be repeated in the future if required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">PCDS, 2018</a>].</li></ul></li></ul><h5>Oral contraceptives</h5><ul><li>Several guidelines recommend use of oral contraceptives as an alternative to oral antibiotics in women with moderate to severe acne where topical treatments have failed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Bettoli, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Asai, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">PCDS, 2018</a>].</li><li>The risks and benefits must be assessed on an individual basis — the combination of oestrogen with cyproterone and some other progestogenic hormones is associated with a 1.5-2 fold increased incidence of venous thromboembolism (VTE) compared with levonorgestrel-containing combined pills [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">FSRH, 2013</a>].<ul><li>Cyproterone with ethinylestradiol (co-cyprindiol) is licensed as a second-line treatment for women with severe acne when treatment with topical therapy or systemic antibiotics has failed. It should not be used solely as a contraceptive and use of an additional hormonal contraceptive with co-cyprindiol is contraindicated. Continuation of treatment should be evaluated regularly by a clinician and the patient advised to be vigilant for signs and symptoms of VTE [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">MHRA, 2013</a>].</li><li>The Faculty of Sexual and Reproductive Health guidance on Combined Hormonal Contraception has highlighted the increased risk of thrombosis associated with use of co-cyprindiol pills (Dianette® and Clairette®) — all women being prescribed combined hormonal contraceptives, including Dianette® should be alerted to the increased risk of thrombosis compared to non-use or use of levonorgestrel-containing combined pills. However, the absolute risk is still low if prescribed appropriately and is less than the risk associated with pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">FSRH, 2013</a>].</li><li>A meta-analysis of 32 randomized controlled trials found that although antibiotics may be superior at 3 months, combined oral contraceptives (COCPs) are equivalent to antibiotics at 6 months in reducing acne lesions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Koo, 2014</a>].<ul><li>The weighted mean inflammatory lesion reduction following a 3-month course of oral antibiotic treatment was found to be 53.2% compared to 35.6% for a 3-month course of COCPs.</li><li>The weighted mean inflammatory lesion reduction following a 6-month course of oral antibiotic treatment was 57.9% compared to 61.9% for a 6-month course of COCPs.</li></ul></li><li>A Cochrane meta-analysis has examined the effectiveness of combined oral contraceptives (COCPs) for the treatment of facial acne compared to placebo or other active therapies in women (n = 31 trials, 12,579 women). Six COCPs were evaluated in placebo-controlled trials and found to be effective in reducing inflammatory and non-inflammatory facial acne lesions. Few important and consistent differences could be identified between COCP types in their effectiveness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Arowojolu et al, 2012</a>].</li></ul></li></ul><h5>Choice of oral contraceptive</h5><ul><li>A Cochrane systematic review found that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Arowojolu et al, 2012</a>]: <ul><li>Combined oral contraceptives (COCs) containing chlormadinone or cyproterone acetate seem to improve acne better than levonorgestrel, however, this finding was based on limited evidence.</li><li>A COC containing drospirenone was more effective than norgestimate or nomegestrol acetate, but the trials used different methods to assess acne severity assessments.</li><li>Comparisons between other COCs were either conflicting or showed no significant difference in their ability to reduce acne.</li></ul></li><li>The information that third or fourth generation COCs may be preferred is based on expert opinion in a consensus guideline and a narrative review.<ul><li>No definitive data on efficacy and tolerability comparing the available COCs are available in the literature although, theoretically, the ones containing progestins with an anti-androgenic potential and no androgenic effect should be preferred [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Bettoli, 2015</a>]. </li><li>Acne may be exacerbated if females are taking oral contraceptives or have progestin implants with androgenic activity. Third- or fourth-generation pills with anti-androgenic activity are preferred [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>]. </li></ul></li></ul><h5>Referral for consideration of isotretinoin</h5><ul><li>Expert opinion in guidelines and review articles is that people who have or are at risk of scarring or depigmentation due to acne and those with significant psychological distress should be referred for specialist treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Archer et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Nast, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">PCDS, 2018</a>].</li></ul><h5>Follow up</h5><ul><li>Several guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Asai, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Nast, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">PCDS, 2018</a>] recommend follow up to determine the need for ongoing patient education, escalation of treatment or maintenance therapy.<ul><li>Side-effects and lack of knowledge about acne treatments are the two main reasons for non-adherence — appropriate dosage and application of treatment, the slow onset of action of acne treatments and possible adverse events should be discussed when treatments are initiated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>].</li><li>Topical agents should be applied to the entire area, not just visible spots so that microcomedones in surrounding skin which are not clinically visible are also treated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>].</li></ul></li></ul><h5>Maintenance therapy</h5><ul><li>Maintenance therapy helps to prevent recurrence of acne by suppressing development of microcomedones which can be present in normal looking skin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>].</li><li>A systematic review (n = 5 randomised controlled trials [983 participants] and 3 non randomised controlled trials [261 participants]) concluded that evidence was insufficient to recommend specific maintenance therapies as initial treatments before the maintenance phase varied markedly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Dressler, 2016</a>].</li><li>The European evidence-based guideline for the treatment of acne [<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Nast, 2016</a>]  states that topical retinoids, topical retinoids/benzoyl peroxide and azelaic acid are effective on microcomedones. Long-term or maintenance use of topical or systemic antibiotics should be avoided.</li></ul><!-- end field 37c1c536-83b7-4973-b63e-82139684d0d3 --><!-- end item a5f25f97-66a5-4493-895a-f4880f3308e8 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}